在NMPA批准后,Everest药物公司在2026年3月在中国推出了VELSIPITY®治疗性结肠炎. Everest Medicines launched VELSIPITY® in China for ulcerative colitis in March 2026, following NMPA approval.

埃弗雷斯特药品公司已在中国大陆推出VELSIPITY® (胺平片) 治疗中度至重度活跃性性结肠炎,该药物已于2026年2月获得NMPA批准,并将在一个月内上市. Everest Medicines has launched VELSIPITY® (etrasimod arginine tablets) in mainland China for moderately to severely active ulcerative colitis, approved by the NMPA in February 2026 and available within a month. 该药物在美国准则中被推荐为一线治疗,在试验中显示出很强的功效,包括第40周的48.1%的临床缓解和51.9%的深度肌肉愈合。 The drug, recommended as a first-line treatment in U.S. guidelines, showed strong efficacy in trials, including 48.1% clinical remission and 51.9% deep mucosal healing at week 40. 目前,在7个城市的8个主要医院和通过互联网医院都可以获得这种服务,因为预计到2031年将达到150万个IBD病例。 It is now accessible in eight major hospitals across seven cities and via internet hospitals, responding to rising IBD cases projected to reach 1.5 million by 2031.